Erasca (ERAS) News Today → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free ERAS Stock Alerts $2.52 -0.11 (-4.18%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 12:15 PM | marketbeat.comErasca (NASDAQ:ERAS) PT Lowered to $4.00 at The Goldman Sachs GroupThe Goldman Sachs Group reduced their target price on Erasca from $7.00 to $4.00 and set a "buy" rating on the stock in a report on Tuesday.May 25, 2024 | americanbankingnews.comErasca, Inc. (NASDAQ:ERAS) Director Purchases $181,600.00 in StockMay 23, 2024 | finance.yahoo.comIndependent Director of Erasca Picks Up 14% More StockMay 23, 2024 | insidertrades.comErasca, Inc. (NASDAQ:ERAS) Director Alexander W. Casdin Purchases 80,000 SharesMay 23, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Erasca, Inc. Issued By Capital One Financial (NASDAQ:ERAS)May 23, 2024 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) to Post Q2 2024 Earnings of ($0.17) Per Share, Capital One Financial ForecastsErasca, Inc. (NASDAQ:ERAS - Free Report) - Investment analysts at Capital One Financial boosted their Q2 2024 EPS estimates for Erasca in a report issued on Monday, May 20th. Capital One Financial analyst N. Quibria now anticipates that the company will earn ($0.17) per share for the quarter, upMay 23, 2024 | americanbankingnews.comErasca, Inc. (NASDAQ:ERAS) to Post Q2 2024 Earnings of ($0.15) Per Share, HC Wainwright ForecastsMay 22, 2024 | marketbeat.comInsider Buying: Erasca, Inc. (NASDAQ:ERAS) Director Acquires 80,000 Shares of StockErasca, Inc. (NASDAQ:ERAS - Get Free Report) Director Alexander W. Casdin purchased 80,000 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average cost of $2.27 per share, with a total value of $181,600.00. Following the purchase, the director now owns 573,974 shares in the company, valued at approximately $1,302,920.98. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.May 22, 2024 | marketbeat.comQ2 2024 EPS Estimates for Erasca, Inc. (NASDAQ:ERAS) Increased by AnalystErasca, Inc. (NASDAQ:ERAS - Free Report) - Equities researchers at HC Wainwright upped their Q2 2024 earnings per share (EPS) estimates for Erasca in a research note issued to investors on Monday, May 20th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings ofMay 21, 2024 | finance.yahoo.comErasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional SharesMay 21, 2024 | globenewswire.comErasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional SharesMay 21, 2024 | americanbankingnews.comErasca (NASDAQ:ERAS) Given New $5.00 Price Target at HC WainwrightMay 20, 2024 | markets.businessinsider.comErasca Inc. Earns Buy Rating: Strategic Acquisitions and Promising Pipeline PositioningMay 20, 2024 | markets.businessinsider.comOptimistic Outlook for Erasca: Strategic Growth and Financial PrudenceMay 17, 2024 | msn.comErasca stock climbs 10% amid pipeline restructuring, equity offeringMay 16, 2024 | globenewswire.comErasca Announces Strategic In-Licensing of RAS-Targeting FranchiseMay 16, 2024 | globenewswire.comErasca Announces Pricing of Underwritten Offering of Common StockMay 14, 2024 | markets.businessinsider.comErasca’s Stable Cash Runway and Upcoming Clinical Milestones Secure Buy RatingMay 9, 2024 | marketbeat.comErasca's (ERAS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $8.00 price target on shares of Erasca in a report on Thursday.May 9, 2024 | investorplace.comERAS Stock Earnings: Erasca Misses EPS for Q1 2024May 8, 2024 | globenewswire.comErasca Reports First Quarter 2024 Business Updates and Financial ResultsMay 7, 2024 | finance.yahoo.comErasca to Present at the Bank of America Health Care ConferenceMay 1, 2024 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Sees Large Increase in Short InterestErasca, Inc. (NASDAQ:ERAS - Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 9,480,000 shares, an increase of 6.9% from the March 31st total of 8,870,000 shares. Approximately 10.6% of the shares of the company are short sold. Based on an average daily volume of 783,400 shares, the short-interest ratio is presently 12.1 days.April 24, 2024 | globenewswire.comErasca Announces Three Presentations at the 2024 ASCO Annual MeetingApril 16, 2024 | finance.yahoo.comInstitutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year lossesApril 9, 2024 | fool.comErasca (NASDAQ: ERAS)April 3, 2024 | markets.businessinsider.comErasca’s Promising Naporafenib Data and Financial Stability Merit a Buy RatingApril 2, 2024 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Short Interest Down 8.9% in MarchErasca, Inc. (NASDAQ:ERAS - Get Free Report) was the target of a large decrease in short interest in March. As of March 15th, there was short interest totalling 9,020,000 shares, a decrease of 8.9% from the February 29th total of 9,900,000 shares. Based on an average daily trading volume, of 801,900 shares, the short-interest ratio is presently 11.2 days. Approximately 10.1% of the shares of the stock are short sold.April 2, 2024 | marketbeat.comThe Goldman Sachs Group Boosts Erasca (NASDAQ:ERAS) Price Target to $7.00The Goldman Sachs Group lifted their price target on Erasca from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Tuesday.April 1, 2024 | finance.yahoo.comErasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | seekingalpha.comErasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finanznachrichten.deErasca, Inc.: Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial ResultsMarch 29, 2024 | finance.yahoo.comErasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...March 29, 2024 | markets.businessinsider.comErasca’s Strong Clinical Data and Enhanced Financial Position Support Buy RatingMarch 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)March 28, 2024 | msn.comErasca to get $45M funding via private placementMarch 28, 2024 | marketwatch.comErasca Shares Climb After 4Q Loss Narrows, $45 Million Private PlacementMarch 27, 2024 | investorplace.comERAS Stock Earnings: Erasca Beats EPS for Q4 2023March 27, 2024 | globenewswire.comErasca Announces $45 Million Oversubscribed Private Placement FinancingMarch 27, 2024 | globenewswire.comErasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial ResultsMarch 21, 2024 | msn.comOcugen hits a 52-week high after decision to lower quorum requirementFebruary 27, 2024 | finance.yahoo.comERAS Mar 2024 2.000 putFebruary 17, 2024 | finance.yahoo.comERAS Mar 2024 2.500 callFebruary 15, 2024 | msn.comErasca collaborates with Novartis on cancer therapy trialsFebruary 14, 2024 | finance.yahoo.comErasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 TrialsFebruary 1, 2024 | finance.yahoo.comErasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 9, 2024 | finance.yahoo.comIs Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?January 7, 2024 | benzinga.comErasca Stock (NASDAQ:ERAS), Analyst Ratings, Price Targets, PredictionsJanuary 6, 2024 | msn.comB of A Securities Downgrades Erasca (ERAS)January 3, 2024 | finance.yahoo.comErasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Pioneer Says: “The last crypto bull market has begun.” (Ad)Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble. Click here if you’d like to learn more about these five cryptos… ERAS Media Mentions By Week ERAS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ERAS News Sentiment▼0.920.83▲Average Medical News Sentiment ERAS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ERAS Articles This Week▼192▲ERAS Articles Average Week Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lexicon Pharmaceuticals News Biomea Fusion News Terns Pharmaceuticals News Mereo BioPharma Group News Acelyrin News Neurogene News Verrica Pharmaceuticals News Theravance Biopharma News Annexon News Amarin News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ERAS) was last updated on 5/29/2024 by MarketBeat.com Staff From Our Partners4 Cryptos BETTER than BitcoinTrue Market InsidersWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyHow Biden has already won 2024Porter & CompanyNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss Ratings41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
